ECSP056145A - Beta-carbolinas utiles para tratar enfermedades inflamatorias - Google Patents
Beta-carbolinas utiles para tratar enfermedades inflamatoriasInfo
- Publication number
- ECSP056145A ECSP056145A EC2005006145A ECSP056145A ECSP056145A EC SP056145 A ECSP056145 A EC SP056145A EC 2005006145 A EC2005006145 A EC 2005006145A EC SP056145 A ECSP056145 A EC SP056145A EC SP056145 A ECSP056145 A EC SP056145A
- Authority
- EC
- Ecuador
- Prior art keywords
- useful
- inflammatory diseases
- beta
- carbolins
- treat inflammatory
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- -1 tetrahydrofuranoyl Chemical group 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención proporciona compuestos beta-carbolina de fórmula I: Idonde el Anillo A es un anillo piridinilo, pirimidinilo, morfolinilo, piperidinilo, piperazinilo, pirrolidinilo, piranilo, tetrahidrofuranoilo, ciclohexilo, ciclopentilo o tiomorfolinilo sustituido y R1, R2 y R3 son como se han definido en la memoria descriptiva. Los compuestos son inhibidores de IKK-2 que son útiles para tratar enfermedades mediadas por IKK-2 tales como enfermedades inflamatorias y cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46146803P | 2003-04-09 | 2003-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP056145A true ECSP056145A (es) | 2006-04-19 |
Family
ID=33299818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005006145A ECSP056145A (es) | 2003-04-09 | 2005-11-07 | Beta-carbolinas utiles para tratar enfermedades inflamatorias |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7727985B2 (es) |
| EP (1) | EP1611134A1 (es) |
| JP (1) | JP2006522824A (es) |
| KR (1) | KR20060006031A (es) |
| CN (1) | CN1802375A (es) |
| AU (1) | AU2004230952A1 (es) |
| BR (1) | BRPI0409263A (es) |
| CA (1) | CA2521300A1 (es) |
| CO (1) | CO5700746A2 (es) |
| CR (1) | CR8042A (es) |
| EA (1) | EA009121B1 (es) |
| EC (1) | ECSP056145A (es) |
| HR (1) | HRP20050926A2 (es) |
| MA (1) | MA27837A1 (es) |
| MX (1) | MXPA05010793A (es) |
| NI (1) | NI200500174A (es) |
| NO (1) | NO20054598L (es) |
| OA (1) | OA13115A (es) |
| RS (1) | RS20050832A (es) |
| TN (1) | TNSN05257A1 (es) |
| WO (1) | WO2004092167A1 (es) |
| ZA (1) | ZA200508198B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05010793A (es) | 2003-04-09 | 2005-12-05 | Millennium Pharm Inc | Beta-carbolinas utiles para tratar enfermedades inflamatorias. |
| JP2007532582A (ja) * | 2004-04-09 | 2007-11-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患の処置に有用なβ−カルボリン |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| ES2390135T3 (es) | 2005-11-22 | 2012-11-06 | Merck Sharp & Dohme Corp. | Compuestos tricíclicos útiles como inhibidores de quinasas |
| WO2007106884A2 (en) * | 2006-03-15 | 2007-09-20 | Theralogics, Inc. | Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| WO2008002246A1 (en) * | 2006-06-28 | 2008-01-03 | Astrazeneca Ab | A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient. |
| US20100098641A1 (en) * | 2006-12-13 | 2010-04-22 | William Baker | Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction |
| US20090131422A1 (en) * | 2007-10-23 | 2009-05-21 | Millennium Pharmaceuticals, Inc. | Salts of an IKK inhibitor |
| WO2009054970A1 (en) * | 2007-10-23 | 2009-04-30 | Millennium Pharmaceuticals, Inc. | Mesylate salt of an ikk inhibitor |
| JP5892791B2 (ja) | 2008-05-14 | 2016-03-23 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | 適応免疫における免疫調節物質の効果をモニターするための方法およびキット |
| PL2366699T3 (pl) | 2008-10-02 | 2013-12-31 | Asahi Kasei Pharma Corp | 8-podstawiona pochodna izochinoliny i jej zastosowanie |
| US8748428B2 (en) | 2010-03-30 | 2014-06-10 | Novartis Ag | Use of a PKC inhibitor |
| JP6049216B2 (ja) * | 2011-03-28 | 2016-12-21 | エスジェイティー モレキュラー リサーチ,エス.エル. | メタボリック症候群の処置のための化合物 |
| CN102416014B (zh) * | 2011-09-13 | 2012-11-21 | 河南中医学院 | 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用 |
| CN102391323B (zh) * | 2011-10-18 | 2013-09-25 | 首都医科大学 | 四氢-β-咔啉衍生物、其制备方法及其用途 |
| KR101646916B1 (ko) | 2015-07-13 | 2016-08-09 | 강원대학교산학협력단 | 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물 |
| CN108271369A (zh) | 2015-10-23 | 2018-07-10 | 法尔玛赞公司 | 用于制备色胺及其衍生物的新工艺 |
| CN109593089B (zh) * | 2019-01-24 | 2022-01-28 | 西南大学 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
| CN112824387B (zh) * | 2019-11-21 | 2023-03-21 | 济南尚博生物科技有限公司 | 一种2-甲基烟酸酯及其制备方法和应用 |
| CN117510494B (zh) * | 2023-11-07 | 2024-04-19 | 桂林医学院附属医院 | β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4925099A (en) * | 1998-08-12 | 2000-03-06 | Pfizer Products Inc. | Tace inhibitors |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| MEP28108A (en) * | 2000-03-15 | 2010-10-10 | Sanofi Aventis Deutschland | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| WO2001068648A1 (en) * | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| ATE363473T1 (de) * | 2001-09-19 | 2007-06-15 | Pharmacia Corp | Substituierte pyrazoloverbindungen zur behandlung von entzündungen |
| US9248124B2 (en) * | 2001-11-07 | 2016-02-02 | Millennium Pharmaceuticals, Inc. | Use of inhibitors of IκB kinase for the treatment of cancer |
| ATE406360T1 (de) * | 2003-03-07 | 2008-09-15 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| MXPA05010793A (es) | 2003-04-09 | 2005-12-05 | Millennium Pharm Inc | Beta-carbolinas utiles para tratar enfermedades inflamatorias. |
-
2004
- 2004-04-09 MX MXPA05010793A patent/MXPA05010793A/es active IP Right Grant
- 2004-04-09 JP JP2006509889A patent/JP2006522824A/ja active Pending
- 2004-04-09 CA CA002521300A patent/CA2521300A1/en not_active Abandoned
- 2004-04-09 RS YUP-2005/0832A patent/RS20050832A/sr unknown
- 2004-04-09 HR HR20050926A patent/HRP20050926A2/hr not_active Application Discontinuation
- 2004-04-09 US US10/821,545 patent/US7727985B2/en not_active Expired - Lifetime
- 2004-04-09 CN CNA2004800160170A patent/CN1802375A/zh active Pending
- 2004-04-09 EP EP04759390A patent/EP1611134A1/en not_active Withdrawn
- 2004-04-09 WO PCT/US2004/011080 patent/WO2004092167A1/en not_active Ceased
- 2004-04-09 EA EA200501584A patent/EA009121B1/ru not_active IP Right Cessation
- 2004-04-09 AU AU2004230952A patent/AU2004230952A1/en not_active Abandoned
- 2004-04-09 BR BRPI0409263-5A patent/BRPI0409263A/pt not_active IP Right Cessation
- 2004-04-09 KR KR1020057019268A patent/KR20060006031A/ko not_active Ceased
- 2004-04-09 OA OA1200500279A patent/OA13115A/en unknown
-
2005
- 2005-10-06 NO NO20054598A patent/NO20054598L/no not_active Application Discontinuation
- 2005-10-07 TN TNP2005000257A patent/TNSN05257A1/en unknown
- 2005-10-07 NI NI200500174A patent/NI200500174A/es unknown
- 2005-10-11 ZA ZA200508198A patent/ZA200508198B/xx unknown
- 2005-10-12 CR CR8042A patent/CR8042A/es not_active Application Discontinuation
- 2005-11-04 CO CO05113041A patent/CO5700746A2/es not_active Application Discontinuation
- 2005-11-07 EC EC2005006145A patent/ECSP056145A/es unknown
- 2005-11-09 MA MA28592A patent/MA27837A1/fr unknown
-
2009
- 2009-12-17 US US12/640,335 patent/US20100093713A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054598D0 (no) | 2005-10-06 |
| ZA200508198B (en) | 2007-01-31 |
| NO20054598L (no) | 2005-10-27 |
| JP2006522824A (ja) | 2006-10-05 |
| RS20050832A (sr) | 2007-12-31 |
| MXPA05010793A (es) | 2005-12-05 |
| MA27837A1 (fr) | 2006-04-03 |
| EA009121B1 (ru) | 2007-10-26 |
| BRPI0409263A (pt) | 2006-03-28 |
| KR20060006031A (ko) | 2006-01-18 |
| WO2004092167A8 (en) | 2006-01-05 |
| CA2521300A1 (en) | 2004-10-28 |
| TNSN05257A1 (en) | 2007-07-10 |
| AU2004230952A1 (en) | 2004-10-28 |
| EP1611134A1 (en) | 2006-01-04 |
| CO5700746A2 (es) | 2006-11-30 |
| CN1802375A (zh) | 2006-07-12 |
| EA200501584A1 (ru) | 2006-06-30 |
| NI200500174A (es) | 2006-04-17 |
| OA13115A (en) | 2006-11-10 |
| HRP20050926A2 (en) | 2006-06-30 |
| US20040235839A1 (en) | 2004-11-25 |
| CR8042A (es) | 2006-05-30 |
| US20100093713A1 (en) | 2010-04-15 |
| WO2004092167A1 (en) | 2004-10-28 |
| US7727985B2 (en) | 2010-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI200500174A (es) | Beta-carboniles útiles para el tratamiento de enfermedades inflamatorias | |
| CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO6870032A2 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| MX2022001181A (es) | Inhibidores de kif18a. | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| MX2019005232A (es) | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| ECSP14013148A (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| UY29458A1 (es) | Heterociclos sustituidos y usos de los mismos | |
| ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
| DE602005025803D1 (de) | Stereoisomerisch angereicherte 3-aminocarbonyl-bicyclohepten-pyrimidindiamin-verbindungen und ihre verwendungen | |
| UY27834A1 (es) | Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos. | |
| MY146548A (en) | Certain chemicals entities, compositions, and methods | |
| CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| UY30627A1 (es) | Inhibidores de metaloproteasas derivados de heterociclos | |
| TN2009000389A1 (en) | Pyrido [2,3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer | |
| ECSP11010867A (es) | Compuestos novedosos de fenilamino-isonicotinamida | |
| CO2023010694A2 (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| ECSP066986A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
| ECSP045477A (es) | COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS. | |
| MX2025002519A (es) | Derivados de piridazinona como degradadores de kat2 para el tratamiento de trastornos proliferativos |